Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Goldman Sachs Downgrades Spark Therapeutics (NASDAQ:ONCE) to Neutral Having $58.0 Target from Buy Rating

Goldman Sachs Analyst Rating Change Spark Therapeutics NASDAQ:ONCE

Spark Therapeutics (NASDAQ:ONCE) Change of Rating

Spark Therapeutics (NASDAQ:ONCE) was cut by equity analysts at Goldman Sachs from Buy rating to Neutral rating in a note shared with investors on Thursday, 14 December. The firm from today has a $58.0 target on the stock. Goldman Sachs’s target indicates a potential downside of -28.31 %.

In spite of the firm’s rating downgrade NASDAQ:ONCE is now trading 0.11% higher at $74.11 as of 8:15 AM New York time. Spark Therapeutics shares have [From2] 0% over the past 200 days, while the S&P 500 Index has risen 6.00% over the same time period.

According to data compiled by Thomson Reuters, Spark Therapeutics (NASDAQ:ONCE)’s stock is covered by 9 equity analysts across the Street, with 1 analysts giving it a Sell rating, 5 a Buy rating, while 3 consider it a Hold. The 12-month consensus target price for the stock is $58.44, which reflects an downside potential of 21.14% over the current price.

Institutional Ownership

Rock Springs Capital Management Lp had the largest stake with ownership of 625,000 shares as of q2 2015 for 2.35% of the long stock exposure. Brookside Capital Management Llc is another notably bullish institutional investor who is possessing 367,314 shares of Spark Therapeutics or 1.43% of their long stock exposure. Also, Ecor1 Capital Llc have 1.26% of their long stock exposure invested in the company for 68,600 shares. The New York-based fund Deerfield Management Co disclosed it had acquired a stake worth about 1.03% of the institutional investor’s stock portfolio in Spark Therapeutics. The New York-based fund Baker Bros. Advisors Lp is also positive about the stock, possessing 368,000 shares or 0.72% of their long stock exposure.

Spark Therapeutics (NASDAQ:ONCE) Profile

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

Spark Therapeutics (NASDAQ:ONCE) traded up 0.11% on 14 December, hitting $74.11. A total of 177,872 shares of the company’s stock traded hands. This is down from average of 518,672 shares. Spark Therapeutics has a 52 week low of $47.03 and a 52 week high of $91.75. The company has a market cap of $2.74B and a P/E ratio of 0.

Get the latest Spark Therapeutics (NASDAQ:ONCE) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Goldman Sachs Downgrades Spark Therapeutics (NASDAQ:ONCE) to Neutral Having $58.0 Target from Buy Rating appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Goldman Sachs Downgrades Spark Therapeutics (NASDAQ:ONCE) to Neutral Having $58.0 Target from Buy Rating


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription